The outlook revision is based on a number of factors, including Moody’s Investors Service’s expectation that Vidant Health will maintain its current cash flow levels.
Moody’s also affirmed the “A1” rating assigned to Vidant Health’s $440 million of rated debt. The affirmation is based on Vidant’s strong market position in its service area.
More articles on healthcare finance:
Trump pledges to combat rising drug prices, ending pharma’s election ‘honeymoon’
Mutual of America Capital Management reduces stake in LifePoint
6 hospital CFOs in the headlines
